Nexgram can't move because retailers hold 40% of co shares, so don't expect retailers to goreng the share lar if BOD/major share holders don't dare to push up the share price.....
OVER ALL MARKET IS GETTING SOLID....$$ infact LOCKDOWN is A BOON ( DAMN GOOD) to STOCK MARKET Proven during MCO 1 = $$ # WHAT'S MORE WHEN THE STOCK IS COVID &VACCINE RELATED SUCH AS NEXGRAM = $$$
MCO ( PKP ) is A BLESSING to the stock market.....The market become super hot when Genting Casino is closed . No Magnum 4D , TOTO & what not...so the stock market BOOM $$$$$ Remember during the last MCO 1 , our stock market steaming like no tomorrow even hit the record daily volume of 27 Billions Units . Thanks to retailers who stormed the market - infact many time retailers beat the local institutions in term of daily volume . .
# OUR NEXGRAM to be the BEST BET for COVID -VACCINE related stock . Still the CHEAPEST $$
PETALING JAYA: The emergency declared by the King is not a form of military coup.
“No curfew order will be executed. Instead the civilian government will continue to function as usual,“ PM Moodeen said in a televised live broadcast today.
# those pressed the panic button ( Cut Loss ) just now ....NOW in MAD frustrating...!! hmmm...8Dragon@OKU2020 oledi cut birds liao...
@8dragon. Pada pandangan saya Nexgram sekarang masih berada DIMEDAN PERANG VAKSIN. Berjaya atau gagal keputusan akhirnya masih belum kita peroleh. HE HE.
Nexgram to me is an empty drum, talking alot about securing contracts, but finally ended with empty handed...Pharmaniaga and Dpharma no need to compete to secure vaccines contracts, but the government is awarding them the contracts....
Nexgram said Rafarma will be responsible for the supply of Covid-19 products, while Vaccines Lab will be responsible for assisting the newly-formed joint venture company in its authorisation in target markets, as well as facilitating the registration and conduct of local clinical trials of the products, if necessary.
This company very lousy in promoting itself. The directors think just post news is enough. You are a listed company lah dey, you have to sell and market yourself so ppl will buy your stock and you get more working capital to grow.
@Orlando. Nexgram belum di senarai sebagai GN3 kerana ianya telah diberi relief untuk satu tahun. Berikut pandangan saya berkaitan risiko GN3 status bagi nexgram:
......Nexgram will not be classified as a GN3 listed issuer and will not be required to comply with the obligations pursuant to Rule 8.04 and GN3 of the ACE LR for a period of 12 months from the date of this announcement. Nexgram will re-assess its condition and announce whether it continues to trigger any of the criteria in GN3 of the ACE LR upon the expiry of the 12 months from the date of this announcement.
1. MUGC untuk tahun kewangan berakhir 2019 inilah yang buat BURSA triger GN3 dalam tahun kewangan berakhir 2020. Source: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3007846 2. MUGC wujud dalam tahun kewangan berakhir 2019, itulah sebab mengapa ia menjadi calon GN3 berdasarkan MUGC tersebut (tetapi telah DIBERI RELIEF UNTUK SATU TAHUN). Relief tersebut akan dinilai kembali selepas tempoh satui tahun. Bermakna apabila selepas satu tahun dan keadaan yang menyebabkabkan MUCG pada tahun kewangan 2019 pulih, maka Nexgram tidak akan diklasifikasikan di bawah GN3. 4. Sebagai contoh berdasarkan laporan Q1 2021: Nexgram's share holders equity on consolidated basis of its shares (excluding treasury shares): As per QR1 2021 report = RM108 879 189 / RM 212 519 923 = 51.23 % and As per QR4 2020 report = RM89 221 297 / RM 206 519 923 = 43.20 % We can see that the percentage of shareholders equity of its shares was increased and surpassed 50%. 5 The company's condition is better in near future, the percentage of shareholders equity of its shares is more than 50%, no more MUGC will be triggered in 2020, no more worry about GN3 listed issuer. Jadi, GN3 untuk Nexgram dalam jangka pendek ini bagi saya adalah slim chance.
@Orlando. Nexgram FA sehingga last QR masih lagi tidak baik. Saya setuju, jika anda menyatakan bahawa pihak bank sukar untuk beri kemudahan margin untuk membeli saham yang FA nya kurang baik. Kalau ada pengecualian pun mungkin untuk sesetengah syarikat tertentu sahaja.
Informations gathered from the QA at AGM 2020: 1. The company expected to turn profitable earliest in the FY2021. 2. The medical division will potentially contribute to the company growth in near future. A little explanation about the vaccine JV. 3. The Cyberjaya project has been terminated (should be Angkasa Project) caused the big loss in the last QRs (caused by write-off of the land held for property development). The co also has a plan to use the land for medical center to coop with the medical business expansion. 4. Expected revenues from medical (RM10 mil) and construction (RM28 mil) for FY Ended 31 July 2021. 5. The big losses in 4th QR 2020 is from one-off items. Not to be incurred in the next QR reports. 6. The co is positively believes that the medical and construction will be able to contribute for a better net operating cash flow. 7. On the risk to be GN3 listing issuer. The risk is smaller because medical and construction businesses will help the co to increase the shareholders equity and eliminates the possibility of the co to be listed as GN3 listing co.
The new engine of growth for Nexgram.. 1. Covid-19 Test Kits (agreement with MKN/MOH and MTC) 2. Covid-19 Test (via subsidiary in Indonesia) 3. Tracvirus SafeTravelPass (Approved by MKN/ MOH)) 4. Medical gloves and PPE (gown) (contract with MAPU in Indonesia) 5. NexgramBottleVaccine (via subsidiary operation) 6. RM118 mil Subcontract of the Gua Musang Highway (subcontract in progress) 7. Covid-19 VACCINE (plan to manufacture and distribute (JV with Rafarma))
As per the release, Sputnik V currently ranks among top 10 candidate vaccines approaching the end of clinical trials and the start of mass production on the World Health Organization's (WHO) list.
The vaccine's efficacy is confirmed at 91.4 per cent based on data analysis of the final control point of clinical trials in Russia, the release said. Currently, the vaccine's clinical trials are underway in the UAE, Egypt, Venezuela and Belarus while it has been registered in Algeria, Argentina, Belarus, Bolivia and Serbia for inoculation.
Pembekal Sputnik V dari Russia memang mencari partners dari negara lain untuk mengilang vaksin tersebut. Peluang ini terbuka untuk anak syarikat Rafarma di Russia untuk cuba deal untuk JV: . . .....While the Russian Direct Investment Fund (RDIF), which has funded Sputnik V, has deals with multiple countries to supply millions of doses, only about 1.5 million doses of the vaccine have rolled out domestically. ..... The RDIF has said it plans to rely on manufacturing partners in China, India, South Korea and elsewhere to fulfill its major international supply deals
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Singapore88
611 posts
Posted by Singapore88 > 2021-01-11 14:00 | Report Abuse
Kasi kentut kuat kuat